Pharmacology of heparin and warfarin  by Wessler, Stanford & Gitel, Sanford N.
lOB
ANTITHROMBOTIC AGENTS
Pharmacology of Heparin and Warfarin
STANFORD WESSLER, MD, SANFORD N. GITEL, PHD
New York, New York
lACC Vol S, No 6
December 1986 IOB-20B
Thromboembolic obstruction to three major components
of the circulation-arterial, venous and intravascular
foreign surfaces-contributes to premature death and
disability in Western society. In many, but not all, of
these conditions associated with thromboembolism, hep-
arin and warfarin are the drugs of choice. It is the pur-
pose of this presentation to provide some common ground
in the area of anticoagulant prophylaxis that will be of
intrinsic value for decision making in cardiac, cerebral
In regard to the prophylaxis of venous and arterial throm-
boembolism, it is doubtful that many cardiologists would
take issue with the observation that almost every physician
appears to behave as if there were no published guidelines
for prophylaxis and that each practitioner is "therapeutically
on his or her own." What this means in practical tefllls to
individual patients in each of our own communities is that
the therapeutic regimen offered depends on which physician
is consulted, Moreover, within each category of practi-
tioner. prophylaxis depends on the hospital entered, the
service assigned. the specific attending physician respon-
sible for the patient's care and, at some institutions, the
house officer on duty at the time of admission. Private office
and clinic outpatient management is no more standardized.
In recognition of this absence of consensus, it is the purpose
of this presentation to provide some common ground in the
area of anticoagulant prophylaxis that will be of intrinsic
value for subsequent decision making in cardiac, cerebral
and peripheral vascular disease.
Scope of Thromboembolism
Thrombosis is a pathologic process that complicates the
course and contributes to the lethal nature of several major
diseases in Western society. The impact of thromboembo-
lism on mortality and morbidity in the United States is
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and peripheral vascular disease. Only those aspects of
the hemostatic mechanism most relevant to the anti-
thrombotic action of heparin and warfarin are discussed.
Assays for both drugs as well as some practical guidelines
for their use in low, medium and high dose regimens
are outlined. Techniques for improving the benefit/risk
ratio for each drug are specifically detailed.
(J Am Coli Cardiol 1986;8:108-208)
impressive. Arterial thrombosis plays a role in the initiation,
growth and terminal occlusion of the atherosclerotic lesion
and is a major contributor to mortality in acute myocardial
infarction and stroke, the first and third most common causes
of death in the United States.
Venous thromboembolism causes approximately 300.000
patients annually to be hospitalized in the United States;
pulmonary embolism may be the primary or contributory
cause of death in more than 50.000 patients, primarily in
hospitals, rehabilitation centers and nursing homes. Indeed,
in hospitalized adult patients who die, careful autopsy ex-
aminations disclose evidence of antemortem pulmonary em-
bolism in more than 60% of cases.
Thromboembolism induced by contact of blood with for-
eign surfaces is a major unresolved problem in the devel-
opment of artificial organs. either for extracorporeal cir-
culation or for implantation within the heart and blood vessels.
Thus, clinically, thromboembolic obstruction to three major
components of the circulation-arterial, venous and intra-
vascular foreign surfaces-contributes to early death and
disability in our society. In many, but not all, of these
conditions, heparin and warfarin are the drugs of choice,
The Therapeutic Dilemma
However, when one considers the prophylaxis of throm-
boembolism by anticoagulants, one is immediately struck
by a therapeutic paradox, During recent years. there have
been clinical trials (some convincingly reproduced in more
than one center) demonstrating the efficacy of anticoagu-
lation. There have also been reviews on prophylaxis as well
as general and specific guidelines for therapy (1-5), Yet
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the national impact of all these efforts on the use of anti-
coagulants has been marginal at best.
There are, understandably, characteristics of venous
thromboembolism that have contributed to this failure to
invoke prophylaxis. The process is an extremely common
complication of many abnormal states, is difficult to diag-
nose clinically, is a relatively (one hastens to emphasize the
word "relatively") benign process, considering its high in-
cidence, and its lethality is unpredictable. For arterial throm-
boembolism, there is a similar constellation: it is a common
complication, relatively easy to diagnose, but almost in-
variably too late for effective therapy after the event. The
overriding message from these constraints is that physicians
must be prepared, depending on event rates, to treat several
hundreds to several thousands of patients to save one life.
Implicit in this message is that the benefit/risk ratio for the
population to receive therapy must be readily acceptable.
Thus, the practitioner is tom between doing no harm and
accepting the results of clinical trials. However, because
there persists criticism of clinical traits (some certainly jus-
tified) as well as varied interpretations of their results, ap-
propriate anticoagulant prophylaxis for venous and arterial
thromboembolism has had only limited acceptance by the
medical community at large.
The Coagulation Mechanism
Thrombin production. This is described in more detail
here than in the first article of the symposium (6). Figure
I, from which several cofactors and feedback steps have
been deleted, shows that the coagulation sequence, which
involves biochemical amplification, represents a series of
linked sequential reactions in which a parent zymogen is
converted to a serine protease, which in tum catalyzes a
zymogen-protease transition. In the intrinsic system, co-
agulation is initiated by the adsorption of factor XII onto a
vascular surface such as collagen. Both kallikrein and high
molecular weight kininogen are required for the rapid sur-
face activation of factor XII. In addition, high molecular
weight kininogen increases the reactivity of factor XIIa in
the conversion of factor XI to XIa. Factor XIa, itself a serine
protease, converts factor IX to the activated protease factor
IXa, whereupon factors VIII and IXa form a complex, ac-
tivating factor X. Both phospholipid, made available by
aggregated platelets, and calcium are essential for maximal
activation of factor X. In the presence of factor V, calcium
and phospholipid, the serine protease factor Xa subsequently
converts prothrombin to thrombin. The extrinsic system is
triggered by the release of tissue thromboplastin, a protein-
phospholipid mixture that activates factor VII or VIla. To-
gether they serve as cofactors for the activation of both factor
IX and factor X. Once factor Xa is formed, thrombin pro-
duction proceeds as just described.
Thrombin, the final serine protease in the coagulation
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Figure 1. The coagulation sequence. The diagram, from which
several cofactors and feedback steps have been deleted, shows that
the coagulation sequence represents a series of linked sequential
reactIOns in which a parent zymogen is converted to a serine
protease, which in turn catalyzes a zymogen-protease transition.
See text for further details. HMW = high molecular weight;
PL = phospholipid; TPL = tissue thromboplastin. (Reproduced
with permission from Wessler S, Gitel SN [5].)
sequence, cleaves fibrinogen to fibrin, induces platelet ag-
gregation, activates factor XIII and converts factors VIII
and V to highly reactive molecules. For maximal function
of the coagulation sequence, minute quantities of thrombin
are required.
Thrombin has an additional essential role. that of the
transformation of protein C to activated protein C (Fig. 2).
Activated protein C limits thrombosis by destroying factors
VIlla and Va and initiates fibrinolysis. Patients who are
congenitally deficient in protein C are prone to thrombosis
(7,8), which is one indication of the importance of this
protein.
Plasma protease inhibitors. In addition to protein C,
which limits thrombosis, intravascular coagulation is reg-
ulated by several naturally occurring plasma protease in-
hibitors. One of these, antithrombin III, an Q'rglobulin of
approximately 60,000 daltons, helps maintain the fluidity
of blood. More than 85% of the plasma inhibition of throm-
bin is caused by antithrombin III, with Q'2-macroglobulin
being responsible for the remainder. Factor Xa is also in-
hibited by antithrombin Ill, but in contrast, is less sensitive
to Q'rmacroglobulin and is also markedly inhibited by Q'I-
antitrypsin.
Role of genetic defects. The clinical relevance of these
control mechanisms is attested to by a variety of genetic
defects. A 50% deficiency in antithrombin III is associated
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Figure 2. Activation of protein C by thrombin. Thrombomodulin,
a thrombin-binding factor found on endothelial surfaces, is re-
quired for the rapid activation of protein C. Activated protein C,
also a serine protease, inactivates thrombin-altered factors VIII
(VIlla) and V (Va) and makes available a substance that releases
tissue-derived plasminogen activator, which in turn converts plas-
minogen to plasmin. Protein S (not shown) increases the activity
of activated protein C. (Reproduced with permission from Wessler
S, Gitel SN (5).)
with thrombosis (9), whereas an 80% deficiency in a)-
antitrypsin is not. The latter finding may reflect a redundancy
of the inhibitory response; a)-antitrypsin, which inhibits
only factor Xa, can be compensated for by the combined
effects of antithrombin III and a2-macroglobulin, which
inhibit both factor Xa and thrombin, A major reduction in
the level of antithrombin III, however, results in a double
defect, for which the remaining inhibitory activities cannot
compensate. The balance between thrombosis and hemor-
rhage attained by these inhibitors is very subtle. A single
amino acid substitution in the aI-antitrypsin molecule, for
example, converts that protein from an elastase to a thrombin
inhibitor, causing fatal bleeding (10).
Role of factor Va and activated protein C. Factor Xa
can be protected against antithrombin III inhibition by phos-
pholipid and factor Va or by thrombin-treated platelets and
factor Va. In the latter system, antithrombin III has little or
no inhibitory effect on factor Xa, even in the presence of
heparin. As factor Va is degraded by activated protein C,
the protective action of factor Va is presumably lost (Fig.
2). Thus, through the proteolysis of factor Va, activated
protein C anticoagulates not only by decreasing the rate of
thrombin generation, but also by facilitating the inhibition
of factor Xa by antithrombin III. Activated protein C is
itself neutralized by a specific plasma inhibitor.
The Fibrinolytic Sequence
Once intravascular coagulation has been initiated, plas-
minogen is converted to plasmin by the release of endog-
enous tissue plasminogen activator. Plasmin cleaves fibrin
into soluble fragments and degrades fibrinogen, prothrombin
and factors VIII and V. The clinical importance of these
reactions is highlighted by the following observations: re-
current thrombosis has been reported among persons with
abnormally high titers of substances that inhibit plasminogen
activation (11), defective plasminogen (12) or a low fibrin-
olytic response (13); conversely, a congenital deficiency in
the naturally occurring arplasmin inhibitor leads to a bleed-
ing diathesis (14).
Heparin
General Considerations
Heparin acts by markedly accelerating the rate of anti-
thrombin III neutralization of the serine proteases XIIa, XIa,
IXa, Xa and thrombin. Antithrombin III, in the presence or
absence of heparin, however, does not significantly inhibit
factor VIla (15)-a point of clinical importance relevant to
the antithrombotic efficacy of heparin compared with the
coumarin compounds. For example, in total hip arthro-
plasty, where low dose heparin is not effective, warfarin,
which depresses factor VII activity, appears to offer sig-
nificant antithrombotic activity at low doses (16).
Heparin may be given intravenously (by constant infusion
or intermittent bolus) or by subcutaneous injection. The
average half-life of heparin is 90 minutes in normal indi-
viduals, with values ranging from 30 to 360 minutes. The
half-life is dose-dependent, being 40 minutes when 3,000
units are injected intravenously and 69 to 83 minutes when
10,000 units are injected.
In addition to being dose-dependent, the half-life of hep-
arin can be affected by the clinical status of the patient. For
example, after pulmonary embolism, the mean half-life may
decrease to 50% of normal. This is one reason for inter-
mittent intravenous schedules being set at 4 hour rather than
6 hour intervals. The cause of the decreased half-life is
unknown. Venous thrombosis, on the other hand, has no
effect on heparin half-life. In some patients with liver func-
tion abnormalities, the half-life of heparin is reported to be
significantly shortened, whereas in others, an average half-
life 50% greater than normal has been observed. Impaired
renal function has been shown by some, but not all, inves-
tigators to increase heparin half-life. These various disease-
related fluctuations in heparin half-life affect dosage deci-
sions in clinical practice. Finally, the fact that heparin,
unlike coumarin compounds, does not cross the placenta
recommends it as the safer anticoagulant during pregnancy.
Plasma Assays
Two general types of assays measure the action of hep-
arin on coagulation: those determining the effect of the
clotting system in general and those using the rate of specific
clotting protease inactivation. The assays in the first cate-
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gory include the activated partial thromboplastin time and
derivative or related tests. The heparin assays in the second
category include thrombin or factor Xa inhibition deter-
minations.
Either the heparin or the antithrombin III concentration
can be rate-limiting in the inhibition of thrombin or factor
Xa. Thus, if antithrombin III activity is depressed, more
heparin is required to obtain the same antithrombotic effect
as that achieved with less heparin in the presence of normal
antithrombin III values.
Fortunately, the exact plasma heparin level is not clin-
ically relevant. What is relevant, in practice, is the deter-
mination that the plasma contains an adequate quantity of
antithrombin III and the demonstration that heparin has in-
creased the reaction rate between antithrombin III and the
clotting proteases. An activated partial thromboplastin time
or an anti-factor Xa assay will provide this information-
the latter with greater sensitivity than the former. An un-
answered question of great clinical importance is the degree
of the heparin-induced increase in the reaction rate between
antithrombin III and the clotting proteases required to pre-
vent a given clinical thrombotic episode from progressing.
It is because such data have been elusive that the dosage of
heparin has remained empirical unless based on findings
from clinical trials.
Clinical Use (Table 1)
Low dose. In the past several years, controlled clinical
trials (17) in human subjects have made it clear that low
doses of heparin, inadequate in the presence of active throm-
bosis, can prevent venous thromboembolism when given
before surgery and in selected groups of medical patients
in whom intravascular coagulation has not yet been initiated.
The appropriate regimen is one utilizing the minimal amount
of drug necessary to prevent thrombosis, thereby reducing
the risk of major hemorrhage. Because even at low plasma
Table 1. Heparin Treatment Regimens
Dosage* Chmcal
(USP units/24 hr) Route IndicatIOns
Low Subcutaneou~ or Elective general surgery
10,000 continuous
intravenous
20,000 Subcutaneous or Acute myocardial infarction,
continuous congestive heart failure,
mtravenous immobilization. post-acute
venous thromboembolism
Medium Intravenous Acute venou~
25,000 to 50,000 (continuous or thromboembolism
intermittent)
Hight Intravenous MaSSive, acute venous
60,000 to 80.000 (contmuous or thromboembohsm
mtermlttent)
*See text for further details tSee text for qualification
concentrations, heparin is antithrombotic , the appropriate
amount of the anticoagulant depends on the intensity of the
thrombogenic stimulus. In support of this thesis, currently
available clinical trials (18) have indicated that 10,000 USP
units administered every 12 hours subcutaneously will pre-
vent thigh vein rethrombosis, whereas 5,000 units every 12
hours is ineffective. For medical patients at risk of throm-
bosis, 10,000 units administered every 12 hours subcuta-
neously can be recommended for prophylaxis. Higher doses
are required for active thrombosis. For surgical patients
receiving 5,000 units every 12 hours in the intraoperative
period, there is undeniably a small risk of increased bleed-
ing. However, this increase in wound hemorrhage is ex-
ceedingly small and almost invariably minor if (and this
caveat deserves emphasis) two conditions are met: I) the
patient is hemostatically competent, and 2) the patient has
not taken aspirin for 5 days before the elective surgery (17).
Low dose regimens can be effectively administered by
continuous intravenous infusion as well as by the subcu-
taneous route. Opinion is divided as to whether the low
dose regimens should be monitored by the activated partial
thromboplastin time, although the majority of investigators
do not believe such monitoring is required.
Medium dose. Once active deep venous thrombosis or
pulmonary embolism has been diagnosed, low dose heparin
regimens, at least initially, are inadequate. Although there
is no practical technique for determining in an individual
patient the minimal amount of heparin necessary to prevent
further thrombosis, a range as broad as 24,000 to 50,000
USP units/day intravenously has been employed in the large
majority of studies. Clinical trials comparing various hep-
arin schedules for efficacy and safety have not been under-
taken. One of the more widely accepted regimens for the
prophylaxis of venous thromboembolism is an initial bolus
of either 5,000 or 10,000 units followed by a continuous
infusion of 1,000 ± 500 units/h adjusted to maintain the
activated partial thromboplastin time between 1.5 and 2.0
times control. However, other satisfactory regimens using
intermittent intravenous heparin injections have also been
described.
Although not explicitly examined by clinical trial, pub-
lished reports and extensive clinical experience strongly sug-
gest that in a hemostatically competent patient, it is unusual
to encounter spontaneous hemorrhage during the first 48
hours of a heparin regimen of 40,000 to 50,000 units/24 h.
Subsequently, the risk is real and unpredictable, even when
the dose is monitored by the activated partial thromboplastin
time. If medium dose regimens are decreased to 20,000 to
25,000 units/24 h after 2 days of drug administration, the
frequency of spontaneous heparin-associated bleeding will
be markedly reduced while still providing an antithrombotic
effect. The bleeding risk can, of course, be further reduced
by eliminating platelet-suppressive agents and intramuscular
injections.
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The value of the activated partial thromboplastin time in
monitoring heparin dosage is accepted by most. but not all.
authorities. The majority believe that the dose should be
determined by the amount of drug necessary to elevate the
partial thromboplastin time to 1.5 to 2.0 times the control
value. There is agreement that a partial thromboplastin time
before and immediately after the initial heparin bolus is
necessary to indicate that heparin is effectively circulating,
and with a constant intravenous infusion, a daily partial
thromboplastin time is highly desirable. Whether a daily
assay is useful for intermittent intravenous therapy is less
clear, and opinion is divided. For clinical monitoring, there
are no advantages of the whole blood clotting time or anti-
factor Xa assay over the activated partial thromboplastin
time.
High dose. Among patients with acute massive pul-
monary embolism, apart from the increasing use of fibrin-
olytic therapy, clinicians have successfully used as much
as 80,000 USP units/day for the first 24 hours of treatment.
Others have stated that 60,000 USP units/day is adequate.
Because there are no guidelines from clinical trials, these
large doses should be reserved for patients in or near shock
and reduced to the medium dose range 12 to 24 hours after
therapy is instituted and then further reduced as clinical
progress dictates.
There are anecdotal reports (19,20) of the administration,
in massive pulmonary embolism, of as much as 100,000 to
120,000 units for 12 to 24 hours with prompt reduction to
the medium dose range 12 to 24 hours after therapy is
instituted. Some of the case reports indicate that these high
doses relieve the bronchoconstriction often associated with
extensive pulmonary embolization. Whether doses in excess
of 80,000 units are either necessary or safe for the first 12
to 24 hours of therapy, however, remains to be established.
Of interest, moreover, is the possibility that these large
quantities of heparin may offer an alternative to thrombolytic
therapy for patients in shock secondary to pulmonary em-
boli.
Some support for the lack of systemic bleeding from large
doses of heparin for short periods of time comes from the
experience with open heart surgery during which 20,000 to
40,000 units of heparin may be administered safely in a 2
to 4 hour intraoperative period.
Drug Toxicity
Hemorrhage. For low dose prophylaxis on a regimen
of 5,000 units every 12 hours subcutaneously among he-
mostatically competent surgical patients who have not taken
platelet-suppressive drugs, the risk of wound hematoma is
minor but real, and the decision to invoke heparin prophy-
laxis must be individualized. For a regimen of 10,000 units
every 12 hours subcutaneously in medical or postoperative
patients in whom wound hemostasis has been achieved, the
bleeding risk is less than with regular dose warfarin at a
prothrombin time ratio between 1.5 and 2.0.
The use of heparin after the thrombotic event entails far
greater risk of major hemorrhage and several issues, not all
resolved, need to be addressed. Many investigators believe
that although there is no antithrombotic advantage to con-
tinuous intravenous infusion over intermittent intravenous
injections, the former method entails less hemorrhage.
It is not at all clear, however, that maintaining the ac-
tivated partial thromboplastin time in the so-called thera-
peutic range protects patients against hemorrhage, nor is it
apparent that periodic peaks resulting from intermittent reg-
imens favor hemorrhage. With medium dose therapy, more-
over, many of the reported episodes of major bleeding are
related to risk factors for hemorrhage more overriding than
dose or route of administration. These risk factors include
lack of hemostatic competence before heparinization, du-
ration of therapy, intramuscular injections, invasive pro-
cedures, aspirin use, bodily trauma and recent surgery while
on therapy.
Where quality infusion pumps are not readily available
or cannot be adequately supervised, or early ambulation is
desired, there are some practical advantages to using a hep-
arin lock with an intermittent intravenous protocol. Ac-
cordingly, the choice between the two regimens can be left
to the individual physician at the present time.
Age itself has not been demonstrated to increase the
likelihood of hemorrhage. Among adults, the evidence is
inconclusive that either dose determination by body weight
or the substitution of the calcium for the sodium salt of
heparin has a role in diminishing systemic or local hem-
orrhage. There are studies to suggest that older women may
bleed more frequently than men of comparable age. It has
not been established, however, that if the heparin dose is
diminished to levels of 20,000 to 25,000 units/24 h after 2
days of drug administration, a sex difference in the fre-
quency of bleeding would still exist.
One of the clear implications of this analysis is that in
patients given heparin for overt venous thromboembolism,
the dose should not be fixed over time, but rather adjusted
downward after 48 hours of administration. Although hem-
orrhage complicates the choice of dose schedule, it also
simplifies this therapeutic decision; in practical terms, the
risk of hemorrhage controls dose, especially after 2 days of
heparinization.
Thrombocytopenia. Two distinct platelet phenomena
are associated with the administration of heparin. The minor
effect is an almost universal, transient and slight decrease
in circulating platelets that occurs promptly after each in-
travenous injection. The most likely mechanism is a tem-
porary sequestration of platelets that is of no clinical im-
portance. The major effect is a rare but persistent and severe
thrombocytopenia developing from the Irst to the 21rst day
after drug administration, independent of dose or route of
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administration. The defect most likely has an immunologic
basis. Although the frequency varies from °to 30% in
clinical reports, the probable frequency nationally is on the
order of 1 to 2%. If platelet counts are monitored daily for
the first 3 weeks of therapy and heparin discontinued when
the platelet count falls below 100,000, the platelet count
will return toward normal values within 2 to 5 days. As a
result, hemorrhage attributable to this type of thrombocy-
topenia will be largely avoided, and the still perplexing and
controversial phenomenon of paradoxic thromboembolism,
usually arterial, in association with heparin-induced throm-
bocytopenia may be aborted. Rarely, a clinically apparent
thrombotic event may occur as the platelet count is declining
but before the count enters the thrombocytopenic range.
Depression of antithrombin III. Heparin has been re-
ported to cause a depression in the quantity of plasma an-
tithrombin III. The effect of this depression is of debatable
clinical importance because the consequent decrease in an-
tithrombin III activity will be more than offset by the cat-
alytic action of heparin. When therapy is terminated in the
absence of other antithrombotic regimens, however, a pa-
tient with a heparin-induced decrease in the quantity of
antithrombin III must, for the present, be considered to be
in a potentially hypercoagulable state. Therefore, such a
patient may be subject to the risk of thrombosis until the
plasma antithrombin III level has returned to normal, usually
within a 3-day period. One consequence of therapy that may
counteract this effect of antithrombin III depression is ad-
sorption of heparin on the endothelium, with the subsequent
continued release of small amounts of the drug into the
circulation. Nevertheless, the overall effects of abrupt ter-
mination of heparin therapy when antithrombin III has been
depressed are as yet unknown.
Osteoporosis. Osteoporosis associated with heparin has
been reported rarely and is generally found in patients re-
ceiving in excess of 20,000 units/day for 6 months or longer.
This toxic effect has been reported infrequently because it
has been uncommon to use heparin for extended periods of
time. Should heparin be employed long term in place of
warfarin in a variety of patients at risk of recurrent venous
thromboembolism, vertebral fractures secondary to osteo-
porosis may be seen more often. At present, there is no
clear understanding of how heparin induces osteoporosis.
It is important, however, to consider this potential risk fac-
tor, especially in postmenopausal Caucasian women, when
the option of long-term heparin administration arises. Rou-
tine bone X-ray films do not reflect osteoporosis until 50%
of the calcium has been removed from the bone matrix.
More sensitive markers of osteoporosis exist, but are not
currently available for routine clinical use. These markers
include computed tomography and dual photon absorptiom-
etry.
Heparin resistance. Resistance to a dose of heparin
occurs only when there is either a deficiency in the quantity
of plasma antithrombin III or a lack of antithrombin III in
a heparin-binding site. The absence or near absence of an-
tithrombin III renders heparin useless for antithrombotic
therapy. Two congenital conditions, a decrease in the quan-
tity of antithrombin III and a decrease in the capacity of
antithrombin III to react rapidly with clotting proteases, are
associated with the development of thrombosis in the family
members affected. Markedly increased amounts of heparin
or the substitution of oral anticoagulants are required to
achieve an antithrombotic effect among the former group
of congenital deficiencies.
Paralleling these genetic defects in antithrombin /II are
a variety of clinical conditions that induce acquired defi-
ciencies. Decreases in the amount of circulating antithrom-
bin III occur in disseminated intravascular coagulation, mas-
sive venous thromboembolism and severe liver failure.
Because the antithrombotic action of heparin depends on
the plasma antithrombin III concentration, heparin dosage
will vary accordingly. In acute thrombotic states, anti-
thrombin III concentrates (not yet readily available in the
United States) may prove helpful; in chronic situations,
warfarin will be preferable to heparin.
The rebound phenomenon. Although whole blood clot-
ting times obtained after cessation of heparin therapy have
been reported to be shorter than before heparin, this obser-
vation has never been correlated with a thrombotic event.
As noted, however, the possibility exists that the heparin-
induced decrease in antithrombin III may create a hyper-
coagulable state for 1 to 3 days after the cessation of the
drug. This phenomenon at present is only a theoretical risk
and is obviated if the patient is already receiving warfarin
at the time heparin is discontinued.
Contraindications. In general, heparin should not be
employed in patients with the following conditions: a hem-
orrhagic diathesis, hypertension with a diastolic pressure
persistently greater than 105 mm Hg, cerebrovascular hem-
orrhage, major trauma, acute ulceration or overt bleeding
from the gastrointestinal, genitourinary or respiratory tract.
Relative contraindications include osteoporosis, use of platelet-
suppressive agents and thyrotoxicosis treated with radio-
active iodine because of the possibility of gland hemorrhage.
Caution is recommended in the use of heparin in vasculitis,
bacterial endocarditis and pericarditis complicating acute
myocardial infarction because of the danger of hemoperi-
cardium.
Antidotes. Minor bleeding from an excess of heparin
can usually be controlled by discontinuing the drug. For
major bleeding or the threat of significant hemorrhage, spe-
cific therapy is warranted. Blood transfusion will correct
massive blood loss, but is not a specific antidote. Protamine
sulfate remains the drug of choice. The protamines are low
molecular weight proteins. rich in arginine and, therefore,
strongly basic. They combine quickly with heparin to form
salts that are devoid of anticoagulant activity. An equivalent
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amount of protamine sulfate will promptly reverse the an-
ticoagulant effect of heparin. One milligram of protamine
sulfate will neutralize approximately 90 USP units of beef
lung heparin or 115 USP units of porcine gut heparin. Prot-
amine, available as a 1% solution, is administered in a
milligram amount equivalent to half the last dose of heparin
if given promptly after that dose. Because of the short half-
life of heparin, however, if protamine is given 30 minutes
after an intravenous dose of heparin, half as much protamine
may be sufficient for neutralization. An excess of protamine
can itself produce an anticoagulant effect. The drug, ad-
ministered intravenously, is given slowly and carefully over
a 3 minute period to diminish the incidence and severity of
toxic reactions that include hypotension, vasodilation,
bradycardia and dyspnea. Facilities to treat resulting shock
as well as any allergic reactions to protamine should be
available.
Warfarin
Mechanism of action. The minimal requirement for an-
ticoagulant activity of the warfarin molecule is an intact 4-
hydroxycoumarin residue, with position 3 occupied either
by a carbon residue or a hydrogen atom, enabling warfarin
to act as an inhibitor of vitamin K, with major effects on
some of the coagulation zymogens.
Six vitamin K-dependent proteins involved in the co-
agulation sequence (factors II, VII, IX and X and proteins
C and S) have been isolated, characterized and identified
by biochemical function. Before these proteins are released
into the circulation, they are altered by a series of vitamin
K-dependent reactions, converting glutamic acid residues
to y-carboxyglutamic acid residues. These residues bind
calcium ion, permitting the coagulation proteins to bind to
phospholipids. Warfarin blocks the carboxylation system,
preventing the formation of y-carboxyglutamic acid resi-
dues. For factors II, VII, IX and X, this decreases their
capacity to bind phospholipid for activation.
A second postulated mechanism for warfarin's anti-
thrombotic action in human beings is the release of certain
proteins that are deficient in y-carboxyglutamic acid. Ex-
perimentally, at least one such protein can decrease the rate
at which prothrombin is activated in vitro, thereby retarding
thrombin production. Whether such action is antithrombotic
has not been established. Warfarin also increases the rate
at which plasma inhibits clotting proteases, as measured by
the rate of factor Xa inhibition. Thrombosis-prone families
have been described who have had an isolated defect in this
inhibitory rate.
It is not yet known whether the lack of y-carboxyglutamic
acid affects the activities of proteins C and S. However, the
warfarin-induced depression of protein C or protein S, or
both, could counterbalance the anticoagulant action of the
drug, initially producing a potentially thrombotic state.
Prothrombin time. Modifications of the Quick pro-
thrombin time are the most widely used tests to monitor
warfarin therapy. The lack of standardization of the pro-
thrombin time assay, particularly of the nature and repro-
ducibility of the thromboplastic reagent, has led to striking
discrepancies, which have been further compounded by the
variety of ways in which the data are expressed for clinical
use. This variability has led not only to confusion among
clinicians, but also to different intensities of treatment. Thus,
the same coagulation defect acceptable as therapeutic at one
institution might be considered homeopathic at another or
interpreted as a dangerous overdose at a third. In the United
Kingdom, the establishment of the British comparative
thromboplastin, a standard reagent of human brain origin,
and the British ratio, a national prothrombin time reporting
system, has helped minimize these problems (see the section
on Dose).
Blood for prothrombin time determinations should be
collected in polypropylene or properly siliconized glass sy-
ringes and test tubes. If it is collected in regular glass con-
tainers or in some commercially prepared siliconized glass
containers, marked shortening of the prothrombin time may
occur with time, leading to erroneously large increases in
warfarin dosages (21). The effect of glass on the prothrom-
bin time may be minimized if specimens are transferred
within 1 hour to appropriate plastic containers.
International normalized ratios. To decrease the prob-
lems related to lack of standardization, a system of reporting
results based on thromboplastin standards has been devel-
oped. One primary standard, the World Health Organization
international reference thromboplastin, and three secondary
standards, a rabbit brain, a human brain and an ox brain
(Thrombtest) preparation have been calibrated against each
other and assigned international normalized ratios (lNR)
(22,23). With this accomplished, any commercial throm-
boplastin reagent can be calibrated against a related refer-
ence standard, and the calibration curve employed to trans-
late a given reporting method to the international normalized
ratios. Table 2 presents prothrombin time ratio ranges ob-
tained using rabbit thromboplastin (U. S. range) and the
equivalent international normalized ratio range.
Dose
Regular dose. Over the past few decades, the generally
accepted therapeutic range of prothrombin time ratios in the
United States has been 1.5 to 2.5 times control. However,
if the international normalized ratio of 2.0 to 5.0 is employed
as a standard (Table 2), the data make it clear that at the
upper portion of the range (above 2.0), use of the U.S.
rabbit thromboplastin results in an intensity of therapy that
is greater than that accepted for either the British compar-
ative thromboplastin or the Thrombotest used in Europe (I).
The use of warfarin when the prothrombin time ratio with
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Table 2. Intensity Ranges for International
Normalized Ratios (INR) Equivalent to U,S.
Ratios Using Rabbit Thromboplastins for
Prothrombin Time Determinations
Coumarin
Dose INR U.S
Intensity Range Range
Low 2.0 to 3 5 1.3 to 1.7
Medium 3.0 to 4 2 1.6 to 1.9
High 3.9 to 5 0 1.8 to 2.1
rabbit thromboplastin exceeds 2,0 accounts, to a large ex-
tent, for the apparently greater number of bleeding com-
plications in this country than are reported abroad.
It is prudent, therefore, with a rabbit thromboplastin
yielding a control prothrombin time of 11 to 12 seconds, to
adjust the warfarin dosage to produce a prothrombin time
ratio of 1.5 and not to exceed a ratio of 2.0. In rare cases,
the ratio may be maintained at 2,0, such as when one is
treating patients with a prosthetic heart valve in whom sys-
temic thromboembolism is feared. One must be prepared to
accept a greater risk of bleeding in any patient, however,
when the prothrombin time ratio exceeds 2,0. A possible
alternative to increasing warfarin prophylaxis to potentially
hemorrhagic levels in patients with prosthetic heart valves
is to augment therapy with dipyridamole (but not with as-
pirin) (24). Platelet antiaggregants alone or in any combi-
nation are no substitute for warfarin, however. All patients,
moreover, should be cautioned against taking aspirin in any
form while taking warfarin because this combination will
increase the likelihood of bleeding,
In summary, for many, but not all, patients requiring
standard warfarin prophylaxis, a prothrombin time ratio of
1.5 employing rabbit thromboplastin may be effective and
will markedly decrease the risk of hemorrhage that is as-
sociated with higher prothrombin time ratios. As further
trials are completed, this ratio may be decreased to 1,3 or
even less for some groups of patients, particularly, those
with venous thromboembolic disease, and possibly in-
creased toward 2.0 for other patient categories, particularly
those with a mechanical prosthetic heart valve.
Low dose. More than 30 years ago, de Takats (25)
suggested that low doses of oral anticoagulants might be
effective in preventing thrombosis before intravascular co-
agulation was initiated. In the past 5 years, several prom-
ising studies (16,18,26) have indicated that therapeutic ef-
ficacy can be achieved with prothrombin time ratios below
1,5, with a concomitant diminished incidence of hemor-
rhage.
In a persuasive series of clinical studies, the team at
McMaster University (18) demonstrated that a warfarin reg-
imen adjusted to a prothrombin time ratio of approximately
1.3 with use of rabbit thromboplastin inhibited thigh vein
rethrombosis as effectively as did a subcutaneous heparin
regimen of approximately 10,000 units every 12 hours, Both
drugs caused minor but equivalent incidences of hemor-
rhage. Lower doses of heparin (5,000 units every 12 hours)
did not prevent thrombosis, whereas higher doses of war-
farin (prothrombin time ratio 1.5 to 2.0) were associated
with an increased hemorrhagic risk (18).
If the 1.3 prothrombin time ratio obtained with rabbit
thromboplastin in the McMaster trial (18) is compared with
ratios obtained with the human brain reagent employed in
the United Kingdom (26), one recognizes that the McMaster
ratio of 1.3 is comparable with the lower portion of the
British range; in addition, it agrees with effective prothrom-
bin time ratios obtained with an animal model (27). These
small-scale well controlled clinical trials suggest that low
dose warfarin regimens in various groups of patients may
protect against thrombosis and do so with diminished risk
of hemorrhage.
Overlapping heparin and warfarin. When patients are
being switched from heparin to warfarin, conventional wis-
dom used to dictate that the drugs should be overlapped for
2 days because of the 1 to 2 day delay in the peak prothrom-
bin time response. Further elucidation of the pharmacologic
nature of both compounds provides additional support for
maintaining this overlap and, perhaps, even increasing its
duration.
Although heparin administration frequently depresses the
plasma concentration of antithrombin III, the effect of that
depression is debatable during heparin therapy because the
consequent decrease in the antithrombin III concentration
will be more than offset by the increased reaction rate in-
duced by the drug. When heparin therapy is terminated in
the absence of other antithrombotic agents, however, pa-
tients with a heparin-induced decrease in antithrombin III
can be considered to be in a potentially hypercoagulable
state for approximately 3 days until the plasma antithrombin
III level has returned to normal. This is a second reason for
overlapping the anticoagulants for at least that period of
time.
In addition. the warfarin-induced depression of protein
C occurs within the first 12 to 24 hours of drug adminis-
tration at about the same rate as factor VII depression. The
depression of protein C while factors X, IX and II are still
near normal levels may also represent a thrombotic risk and
is further reason for overlapping the use of the two drugs
for several days.
Finally, in view of work in animals indicating that war-
farin has a delayed, additive, antithrombotic effect 6 days
after administration (28), some physicians may wish to ex-
tend the period of overlap to 5 to 6 days-an approach that
has anecdotal support in clinical reports (29,30). If such an
extended overlap is planned, it rarely prolongs the hospital
stay.
Drug-drug interactions. The list of drugs potentiating
or antagonizing the anticoagulant action of warfarin is al-
ready extensive and continually expanding. Classes of com-
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pounding containing commonly used drugs that affect the
prothrombin time by one of several mechanisms include
analgesics, antibiotics, anti-inflammatory agents, diuretic
agents, sedatives and tranquilizers (31). So great are the
number of compounds that rather than maintain such a list,
it is preferable to advise patients receiving warfarin therapy
to report promptly when any drug is deleted from or added
to the therapeutic regimen, including I1onprescription com-
pounds. An analgesic, acetaminophen, can be advised in-
stead of aspirin, which could potentiate bleeding. Frequent
prothrombin time determinations will permit dose adjust-
ments that can prevent either under- or overanticoagulation.
Diet. There are no food restrictions as such for patients
receiving warfarin. The public, however, receives advice
about pharmaceuticals in lay publications. There are state-
ments in this literature that patients maintained on oral an-
ticoagulants should avoid excessive consumption of foods
rich in vitamin K because the compound promotes clotting.
Listed among such foods are leafy green vegetables, as-
paragus, bacon, broccoli, brussels sprouts and beef liver.
Physicians should advise patients that these foods are en-
tirely safe in and of themselves, and should not be restricted
because they are taking warfarin. The point, rather, is that
any major change in diet, as with the addition or deletion
of other drugs, should be reported to the patient's physician
so that drug dosage can be adjusted on the basis of more
frequent determinations of the prothrombin time.
Drug Toxicity
Hemorrhage. For patients on long-term warfarin ther-
apy, it is important to appreciate that bleeding may occur
at unusual sites. Hemorrhage into the bowel lumen, intes-
tinal wall, mesentery, rectus muscle or from the corpus
luteum may simulate an acute abdominal crisis. Similar
considerations apply to genitourinary bleeding that may mimic
a renal tumor. Hematomas may cause carpal tunnel
compression and, rarely, pericardial, adrenal or retroperi-
toneal hemorrhage. Maintaining long-term patients at a pro-
thrombin time ratio at the lower end of the 1.5 to 2.0 range
should minimize hemorrhage, as has been found in Europe.
When to search for the cause of an episode of sponta-
neous bleeding, such asfrom the genitourinary or gastroin-
testinal tracts, can best be decided if the prothrombin time
is obtained within 24 hours of hemorrhage. Experience has
shown that when the prothrombin time ratio is in the range
of 1.5 to 2.0, the likelihood of finding a localized bleeding
lesion is significantly greater than if the prothrombin time
ratio is in excess of 2.5. It is in the former situation that
further efforts to identify the bleeding source should be
undertaken promptly.
Among patients with diabetes who require long-term war-
farin therapy, the question often arises whether anticoag-
ulation represents a risk of vitreous or retinal hemorrhage,
particularly among patients with advanced retinopathy. Not
only are there no data to support such concerns, but trials
of anticoagulants initiated to treat retinal venous occlusion
complicated by retinal hemorrhage have not been associated
with any enhancement of existing ocular bleeding (see in
more detail in Kienast et al. [32]).
Teratogenicity. Fertile women receiving warfarin must
be warned of the risks of teratogenicity if they become
pregnant (33). When pregnancy is an immediate possibility,
consideration should be given to substituting heparin for the
oral anticoagulant. Specific warfarin-induced embryopa-
thies occur in the 6th to the 12th week of pregnancy, and
central nervous system and ocular fetal anomolies may occl.!r
at any time during pregnancy (34). If the patient has been
alerted to notify her physician that her menstrual period is
late by only a few days, there is a human J3-chorionic go-
nadotropin radioimmunoassay specific for detecting preg-
nancy from the 14th postconception day. Even if menses
are delayed by 1 to 2 weeks, there is still time to discontinue
warfarin therapy and markedly diminish, if not avoid, the
likelihood of teratogenesis. If pregnancy is recognized too
late, termination might be considered. Sonography provides
no assistance in making this decision.
Because only an inactive form of warfarin appears in the
milk of nursing mothers, postpartum administration of war-
farin, contrary to popular belief, poses no hazard to the
infant.
Coumarin necrosis. Coumarin-induced necrosis of the
skin and subcutaneous tissues is a rare but striking com-
plication of warfarin therapy and is not to be confused with
simple hemorrhage (35). The lesion appears within 3 to 10
days of drug administration, usually in the lower half of the
body. It occurs particularly in women and in areas of abun-
dant subcutaneous fat, such as the buttocks, breasts, thighs
and abdomen. Beginning as an erythematous patch, frank
hemorrhagic necrosis may develop within 24 hours. No
explanation for this toxic reaction has been established,
although it may be related to protein C depression. It is
clear, however, that the lesion is not a primary hemorrhagic
complication. When coumarin-induced necrosis occurs,
warfarin should be discontinued. If further anticoagulant
therapy is indicated, heparin should be substituted for war-
farin.
Warfarin Resistance
There are rare patients who are congenitally resistant to
coumarin therapy. Some of these individuals may require
75 mg/day of warfarin. In such situations, heparin remains
an alternative choice.
Rebound Phenomenon
After cessation of warfarin therapy, some of the vitamin
K-dependent proteins increase briefly to levels above nor-
mal. These increases are modest and have never been cor-
related with the precipitation of thrombosis. Clinically, it
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is true that after the cessation of warfarin, thrombosis may
develop. In these instances, the patient can be thought of
as having returned to the pretreatment status that favored
intravascular coagulation, rather than involving the concept
of a rebound effect of the drug.
Contraindications. Oral anticoagulants should not be
employed in patients with the following conditions: preg-
nancy; a hemorrhagic diathesis; hypertension with a dia-
stolic pressure persistently greater than 105 mm Hg; cere-
brovascular hemorrhage; major trauma; active ulceration or
overt bleeding from the gastrointestinal, genitourinary or
respiratory tracts; inadequate laboratory facilities or unsat-
isfactory cooperation of the patient with the therapeutic reg-
imen.
For other, though less stringent, contraindications, the
risk must be weighed against the benefit of prophylaxis.
These relative contraindications include a fertile woman,
use of platelet-suppressive agents, renal and liver disease
and thyrotoxicosis treated with radioactive iodine because
of the possibility of gland hemorrhage. Caution is recom-
mended in the use of warfarin in vasculitis, bacterial en-
docarditis and pericarditis complicating acute myocardial
infarction because of the danger of hemopericardium. Ad-
equate preparation before administration of oral anticoag-
ulants may reduce the hazard of bleeding in disorders such
as malnutrition, vitamin C and K deficiencies, ulcerative
colitis, sprue, steatorrhea and pancreatitis.
Antidotes
The natural vitamin K, (Mephyton, Aquamephyton,
Konakion) in doses of 0.5 to 10 mg effectively reverses a
moderately excessive anticoagulant effect. Some correction
of the prothrombin time is noted within 6 hours, full cor-
rection usually within 24 hours. If the patient is to remain
on warfarin, the dose of vitamin K I preferably should be
limited to 0.5 to I mg. Higher amounts, up to 10 mg, may
be indicated if the patient is not to be maintained on therapy
after the hemorrhage is controlled. Large doses of vitamin
K I may subsequently make the patient resistant to warfarin
for many days, preventing effective anticoagulant therapy
for that time period. Vitamin K, may be administered in-
travenously, subcutaneously or orally. The water-soluble
vitamin K I derivatives are distinctly less effective than is
the natural vitamin.
An immediate reversal of the dotting defect can be achieved
by transfusion of blood, plasma or plasma concentrates rich
in the K-dependent clotting factors. Because these factors
are relatively stable, they remain fully potent in ordinary
ACD-banked blood or banked or lyophilized plasma. Thus,
contrary to widespread belief, fresh plasma is not required
for an antidotal effect. Three units, or 15 mllkg, of blood
or plasma should suffice for an initial effect, providing time
for concomitant vitamin K, administration to exert its action.
In patients with limited cardiac reserve, the recommended
volumes of blood or plasma may precipitate pulmonary edema
unless significant blood loss has occurred. Plasma concen-
trates rich in factors II, VII, IX and X will obviate the
hazard of hypervolemia, but carry with them the risk of
thrombosis and hepatitis.
Comparable Antithrombotic Activities of
Heparin and Warfarin
Clinically, it would be helpful to have available alter-
native antithrombotic drugs of equivalent prophylactic ef-
ficacy and bleeding risk for specific patients or groups of
patients with specific conditions, of which pregnancy is one
example. Data obtained from animal models and clinical
trials 08,27) indicate that 20,000 units of heparin per 24
hours may be equivalent to warfarin doses, resulting in
prothrombin time ratios of 1.2 to 1.3. These anticoagulant
levels have comparable bleeding risks.
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